Denouement and discussion
Bilateral massive nephromegaly is present with echogenic kidneys, radially arranged dilated tubules and 'string of pearl' configuration of small subcapsular cysts. This is a typical appearance of autosomal recessive polycystic kidney disease. 1 Ultrasonographic evaluation of the liver in this patient was normal. This entity, which is now referred to as autosomal recessive polycystic kidney disease and congenital hepatic fibrosis (ARPKD-CHF), 2 is characterized by cysts originating from the proximal tubules in continuity with the nephrons. This pathologic feature was first recognized by Osathanodh and Potter in 1964. 1 The liver disease is due to abnormal formation of the bile duct plates leading to biliary dysgenesis and periportal fibrosis. ARPKD-CHF is currently believed to be caused by a single gene, as patients with widely varying degrees of severity have shown linkage to the same gene locus 6p21. This gene has been termed as PKHD1 (polycystic kidney and hepatic disease, gene 1). The protein that is encoded by this gene is called fibrocystin and is involved in collecting tubule and biliary duct formation, although the exact function is not known. 3 There are two essential features of ARPKD-CHF; renal and hepatic disease. 4 Currently it is recognized that ARPDK-CHF encompasses a varied spectrum of renal and liver disease. The previous division by Blythe and Ockenden into perinatal, neonatal, infantile and juvenile types is therefore rarely used now. 4 However, it is true that the most severe renal disease is usually found in youngest patients, and the most severe liver disease in the older, surviving patients. The mortality of perinatal and neonatal disease is very high, only 50% of patients with ARPKD-CHF survive the neonatal period. 3 Infants were severe renal involvement in utero will have oligohydramnios-induced pulmonary hypoplasia and often die in the immediate postnatal period. 3 If the patient survives the neonatal period, renal involvement leads to renal insufficiency, renal concentrating defects and hypertension. 1 The renal disease; however, is not as predictably progressive as is the hepatic disease. 4 The renal and hepatic diseases are more or less inverse in severity, thus those with severe renal disease may not manifest hepatic disease, or only mild disease, and those with severe hepatic disease manifest often only mild renal disease. 3 All patients with ARPKD-CHF have liver disease at least pathologically. Congenital hepatic fibrosis can occur in other disease including Meckel Gruber syndrome, COACH syndrome, tuberous sclerosis and occasionally autosomal dominant polycystic kidney disease. 3 Portal hypertension is the major complication of congenital hepatic fibrosis. Occasionally, biliary dysgenesis is associated with marked cystic dilatation of the bile ducts, or Caroli's syndrome, which is associated with risk of recurrent cholangitis. Portal hypertension with variceal bleeding, cholangitis and hepatic insufficiency are the most common problems associated with the hepatic component of the disease. 2 The plain radiographic findings of ARPKD-CHF include large flank masses displacing the bowel loops centrally, producing an appearance similar to ascites, and therefore referred to as the pseudoascites sign. 3 Sonographically the disease is characterized by nephromegaly, which in 60% of patients is massive, being more than 4 s.d. above normal for renal volume. 5 The kidneys are often diffusely echogenic. Dilated tubules can be identified in the majority of perinatal and neonatal ARPKD-CHF patients. These are seen as radially arranged anechoic tubules. Macroscopic cysts usually less than 1 cm occur in many patients and may be subcapsular in distribution. A preserved cortical rim is seen, particularly in milder disease, and there may be echogenic pyramids. Discrete hyperechoic foci may occur, which are believed to be calcifications. 2, 5 These echogenic foci are believed to correlate with renal failure. 5 Renal size stabilizes and may decrease over time if the patient survives. Current therapies include management of arterial hypertension, and dietary modifications such as low protein diet. Renal failure can be treated by dialysis or transplant. Detailed studies of fibrocystin and its precise function are now being undertaken. 
